Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2012 Nov;59(5):934-8
Date
06/01/2012Pubmed ID
22648868Pubmed Central ID
PMC3528889DOI
10.1002/pbc.24103Scopus ID
2-s2.0-84866169497 (requires institutional sign-in at Scopus site) 104 CitationsAbstract
Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.
Author List
Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, Recht M, Silverman RA, Tom WL, Pope EAuthor
Yvonne E. Chiu MD Vice Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Adrenergic beta-AntagonistsChild, Preschool
Female
Hemangioendothelioma
Hemangioma
Humans
Infant
Infant, Newborn
Kasabach-Merritt Syndrome
Male
Propranolol
Sarcoma, Kaposi
Skin Neoplasms